Mechanisms of Refractory Hypertension (Carvedilol)

• Status: Withdrawn
• Trial end date: 2020-01-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this protocol is test whether patients with hypertension refractory to antihypertensive treatment have evidence of excessive sympathetic (i.e., nervous system) activity.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Alabama at Birmingham
• Treatments: Carvedilol; Chlorthalidone

Criteria

Inclusion Criteria:

• Uncontrolled clinic BP (>140/90 mmHg)

• Receiving 5 or more antihypertensive agents including an ACE inhibitor or ARB, calcium channel blocker, and chlorthalidone 25 mg

Exclusion Criteria:

• Current use of an alpha or beta or combined alpha-beta antagonist

• Known allergy to alpha-beta antagonists

• CKD (eGFR <40 ml/min/m2)

• MI, stroke or episode of CHF exacerbation within 3 months

• Bradycardia <50 bpm; history of 2nd or 3rd degree heart block unless treated by a pacemaker

• Pregnant or breast-feeding women

• Known hypersensitivity to chlorthalidone or other sulfonamide-derived drugs